Mirati presents data on drug with tough-to-reach target, setting up competition with Amgen
An analyst noted that Mirati's MRTX849, a KRAS G12C inhibitor, is six to nine months behind Amgen's AMG 510, but that the market has room for both. The data presented were on patients with lung and colorectal cancers.